Prosecution Insights
Last updated: October 04, 2026
Application No. 18/090,575

NEUTRON CAPTURE THERAPY APPARATUS AND OPERATION METHOD OF MONITORING SYSTEM THEREOF

Non-Final OA §103
Filed
Dec 29, 2022
Priority
Jul 03, 2020 — CN 202010631538.8 +2 more
Examiner
OSENBAUGH-STEWART, ELIZA W
Art Unit
2881
Tech Center
2800 — Semiconductors & Electrical Systems
Assignee
Neuboron Therapy System Ltd.
OA Round
3 (Non-Final)
73%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
503 granted / 689 resolved
+5.0% vs TC avg
Strong +17% interview lift
Without
With
+16.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
43 currently pending
Career history
735
Total Applications
across all art units

Statute-Specific Performance

§101
3.3%
-36.7% vs TC avg
§103
48.6%
+8.6% vs TC avg
§102
18.2%
-21.8% vs TC avg
§112
25.3%
-14.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 689 resolved cases

Office Action

§103
DETAILED ACTION This Office action is in response to the request for continued examination filed on September 8th, 2026. Claims 1 and 3-21 are pending, with claim 21 being new. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Interpretation The claims recite “real-time neutron dosage detected by the detection system” (multiple claims, including the independent claim). Neutron dosage is understood to mean the dose, which accumulates over time. Therefore, “real-time detection” will be considered to be the real-time output of the integrator, rather than a real-time output of the detector itself. The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. This application includes one or more claim limitations that do not use the word “means,” but are nonetheless being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, because the claim limitation(s) uses a generic placeholder such as system or part that is coupled with functional language without reciting sufficient structure to perform the recited function and the generic placeholder is not preceded by a structural modifier. Such claim limitation(s) is/are: “a neutron beam irradiation system configured to generate a neutron beam,”, “a detection system configured to detect real-time irradiation parameters during a neutron beam irradiation therapy,”, “an input part configured to input preset irradiation parameters”, “a determination part configured to determine whether irradiation parameters are needed to be corrected,” and “a correction part configured to correct a part of the irradiation parameters,” in claims 1-20; “a storage part configured to store irradiation parameters,” in claims 5-7, 13, 15, and 20 “a control part configured to perform a therapy plan according to the irradiation parameters stored in the storage part,” in claims 5-7 and 20; “a reading part configured to read the real-time irradiation parameters detected by the detection system” in claims 5-7, 13, and 20; and “a calculation part configured to calculate the irradiation parameters stored in the storage part,” in claims 6-7 and 13. Because this/these claim limitation(s) is/are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, it/they is/are being interpreted to cover the corresponding structure described in the specification as performing the claimed function, and equivalents thereof. If applicant does not intend to have this/these limitation(s) interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, applicant may: (1) amend the claim limitation(s) to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph (e.g., by reciting sufficient structure to perform the claimed function); or (2) present a sufficient showing that the claim limitation(s) recite(s) sufficient structure to perform the claimed function so as to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1 and 3-21 is/are rejected under 35 U.S.C. 103 as being unpatentable over US 2018/0250528 (Liu et al.) in view of US 2019/0054320 (Owens et al.). Regarding claim 1, Liu et al. discloses a neutron capture therapy apparatus, comprising a neutron beam irradiation system configured to generate a neutron beam (fig. 3, elements 10 & T), a detection system configured to detect real-time irradiation parameters during a neutron beam irradiation therapy (fig. 3, element 60), and a monitoring system configured to control the whole neutron beam irradiation process (fig. 3, element 70) and comprising a correction part configured to correct a part of the irradiation parameters, (‘the charged particle beam is adjusted and the irradiation dose is controlled’ P 14, where it is understood that the corrected parameters must be calculated for the control to adjust them). Liu et al. does not disclose an input part configured to input preset irradiation parameters. Owens discloses a particle therapy apparatus including an input part configured to input preset irradiation parameters (“The graphical user interface may also provide a menu of commands for operator selection, as well as a programming interface so that the operator may enter a predetermined set of machine instructions and parameters.” P 39). It would have been obvious to a person having ordinary skill in the art at the time the application was filed to include an input part such as the one in Owens et al. in the neutron capture therapy device of Liu et al. so that the desired dose and other beam parameters could be entered by a user. Liu et al. also does not disclose a determination part configured to determine whether the irradiation parameters are needed to be corrected, where the correction occurs in response to the determination part determining that the irradiation parameters are needed to be corrected and the determination part of the monitoring system determining that the irradiation parameters are needed to be corrected, in response to one of plurality of conditions being met. It would have been obvious to a person having ordinary skill in the art at the time the application was filed to include a determination part to determine whether the irradiation parameters are needed to be corrected to reduce computational burden by ensuring that such correction is only carried out when needed. Finally, Liu et al. does not disclose that the conditions include: a ratio of a real-time neutron dosage detected by the detection system to a preset neutron dosage being greater than or equal to a preset value; wherein the correction part adjusts a neutron dosage rate to be a first neutron dosage rate less than a preset neutron dosage rate such that a total irradiation time is increased, in response to the ratio of the real-time neutron dosage to the preset neutron dosage being greater than or equal to the preset value. It would have been obvious to a person having ordinary skill in the art at the time the application was filed to modify the apparatus of Liu et al. to trigger a reduction in doseage rate when the cumulative dose is nearly complete because this will prevent accidental overdosage. Regarding claim 3, Liu et al. in view of Owens et al. disclose the neutron capture therapy apparatus of claim 1, wherein the correction part adjusts the neutron dosage rate to be the first neutron dosage rate less than the preset neutron dosage rate, in response to the ratio of the real-time neutron dosage to the preset neutron dosage being greater than or equal to 97% (obvious as a matter of routine optimization or experimentation, the disclosure never suggests that this value is critical and any value nearing 100% could be considered a reasonable cut-off, with the value chosen being a trade-off between less danger of overdosage with a lower cut-off and shorter irradiation times with a higher cut-off). Regarding claim 4, Liu et al. in view of Owens et al. disclose the neutron capture therapy apparatus of claim 3, wherein the first neutron dosage rate is comprised between 1/5 and 1/2 of the preset neutron dosage rate (obvious as a matter of routine optimization or experimentation, the disclosure never suggests that this range is critical and any value significantly less than the preset neutron dosage rate could be considered reasonable as a way to reduce the chance of accidental overdosage, with the value chosen representing a trade-off between less risk of overdosage at lower rates and shorter irradiation times at higher rates.). Regarding claim 5, Liu et al. in view of Owens et al. disclose the neutron capture therapy apparatus of claim 1, wherein the monitoring system further comprises a storage part configured to store irradiation parameters (obvious to include a storage part because the control will need repeated access this information and storing it ensures access to the preset values even if the values are removed at the input part), a control part configured to perform a therapy plan according to the irradiation parameters stored in the storage part (fig. 3, element 70, wherein ‘the charged particle beam is adjusted and the irradiation dose is controlled’ P 14), and a reading part configured to read the real-time irradiation parameters detected by the detection system ('detection device is used for real-time detection' abstract, where reading the detection signal is inherent in the use of it of the correction part). Regarding claim 6, Liu et al. in view of Owens et al. disclose the neutron capture therapy apparatus of claim 5, wherein the monitoring system further comprises a calculation part configured to calculate the irradiation parameters stored in the storage part ('the radiation detection system calculates the intensity of the neutron beam according to detection signal, so that the charged particle beam is adjusted and the irradiation dose is controlled.' P 14), and the determination part determines, according to a calculation result of the calculation part, whether the irradiation parameters to be corrected (inherent in the determination based on ratio of real-time and preset dosage). Regarding claim 7, Liu et al. in view of Owens et al. disclose the neutron capture therapy apparatus of claim 6, wherein the conditions further include a difference between the preset irradiation parameter and the real-time irradiation parameter calculated by the calculation part (“More particularly, the radiation detection device is an ionization chamber or a scintillator, the radiation detection system calculates the intensity of the neutron beam according to detection signal, so that the charged particle beam is adjusted and the irradiation dose is controlled.” P 14). Liu et al. does not disclose determining that the difference is greater than a first threshold, or the real-time irradiation parameter being greater than a second threshold or less than a third threshold. Comparing values to thresholds to determine if corrections is warranted is common in the art, and it would have been obvious to a person having ordinary skill in the time the application was filed to modify the apparatus of Liu et al. to correct the irradiation parameters when the difference is greater than a first threshold, or equivalently to correct the irradiation parameters when the measured value is greater than a second threshold or smaller than a third threshold, because larger differences, or equivalently values that are a significantly greater or smaller than the target value, indicate a greater need for correction. Regarding claim 8, Liu et al. in view of Owens et al. disclose the neutron capture therapy apparatus of claim 4, wherein the correction part corrects a remaining irradiation time, in response to adjusting, by the correction part, the neutron dosage rate to be 1/5 of the preset neutron dosage rate, and a corrected remaining irradiation time tr is calculated by using a formula (2-4): PNG media_image1.png 82 207 media_image1.png Greyscale where Dtotal is the preset neutron dosage, Dr is the real-time neutron dosage detected by the detection system, and Id is the preset neutron dosage rate (inherent in adjusting the neutron dosage rate to be 1/5 of the preset neutron dosage rate, the irradiation time will need to be adjusted along with the rate for the preset dose to be reached, because dose = rate x time, the formula above merely re-expresses this as remaining time = remaining dose/new rate, were the new rate is 1/5 the preset rate). Regarding claim 9, Liu et al. in view of Owens et al. disclose the claimed invention except for calculating a remaining irradiation time tr is calculated using a formula (2-2) and a formula (2-3), in response to the ratio of the real-time neutron doseage to the preset dosage being less than 97% : PNG media_image2.png 119 210 media_image2.png Greyscale PNG media_image1.png 82 207 media_image1.png Greyscale . It would have been obvious to a person having ordinary skill in the art at the time the application was filed to adjust the remaining irradiation time to account for the actual doseage rate to more accurately time the radiation to ensure the time accurately reflects to the cumulative dose. It would further have been obvious to do this only when the ratio of the real-time doseage is less than 97% because after that the dosage rate is changed and the average doseage rate is no longer an accurate reflection of the doseage rate that can be expected for the remainder of the irradiation. Regarding claim 10, Liu et al. in view of Owens et al. disclose the neutron capture therapy apparatus of claim 1, wherein the monitoring system further comprises a display part configured to display irradiation parameters in real time (fig. 3, element 72). Regarding claim 11, Liu et al. in view of Owens et al. disclose the neutron capture therapy apparatus of claim 3, wherein the monitoring system further comprises a display part configured to display irradiation parameters in real time (fig. 3, element 72). Regarding claim 12, Liu et al. in view of Owens et al. disclose an operation method of the monitoring system of the neutron capture therapy apparatus of claim 1, comprising: inputting, by the input part, the preset irradiation parameters (obvious to input so that an initial set of parameters could be set as desired); and correcting, by the correction part, the irradiation parameters, (‘the charged particle beam is adjusted’ P 14). Liu et al. does not disclose determining, by the determination part, whether irradiation parameters to be corrected, or performing correction in response to the determination part determining that the irradiation parameters are needed to be corrected. It would have been obvious to a person having ordinary skill in the art at the time the application was filed to include such a determination step and perform or not perform the correction based on the determination step to reduce computational burden and adjustment errors by ensuring that such correction is only carried out when needed. Regarding claim 13, Liu et al. in view of Owens et al. disclose the operation method of the monitoring system of claim 12, wherein the monitoring system further comprises a storage part configured to store irradiation parameters (obvious to include a storage part because the control will need to access this information and storing it ensures access), a calculation part configured to calculate the irradiation parameters stored in the storage part ('the radiation detection system calculates the intensity of the neutron beam according to detection signal, so that the charged particle beam is adjusted and the irradiation dose is controlled.' P 14), and a reading part configured to read the real-time irradiation parameters detected by the detection system ('detection device is used for real-time detection' abstract, where reading the detection signal is inherent in the use of it of the correction and calculation parts), and the operation method of the monitoring system further comprise calculating, by the calculation part, the irradiation parameters stored in the storage part ('the radiation detection system calculates the intensity of the neutron beam according to detection signal, so that the charged particle beam is adjusted and the irradiation dose is controlled.' P 14) and the real-time irradiation parameters read by the reading part (inherent in the use of the detected values in the calculation), and the determination part determines, according to a calculation result of the calculation part, whether the irradiation parameters to be corrected (inherent in the determination based on ratio of real-time and preset dosage). Regarding claim 13, Liu et al. in view of Owens et al. disclose the operation method of the monitoring system of claim 12, wherein the monitoring system further comprises a display part (fig. 3, element 72), and the operation method of the monitoring system further comprise displaying, by the display part, irradiation parameters in real time (obvious to display the parameters so that the operator can view them as a method of tracking the progress of the irradiation method). Regarding claim 15, Liu et al. in view of Owens et al. disclose the operation method of the monitoring system of claim 14, wherein the storage part stores the preset irradiation parameters (obvious to store them to ensure they are saved and will not be overwritten or lost during control), and the display part displays a remaining irradiation time and other preset irradiation parameters in real time, before the preset irradiation parameters are corrected (obvious to display remaining time so the operator known long the irradiation will continue, obvious to display the preset parameters so operator can be assured they are correct); and the storage part stores a latest set of corrected irradiation parameters (obvious to store them to ensure they are saved and will not be overwritten or lost during control), and the display part displays a corrected remaining irradiation time and a latest set of other corrected irradiation parameters in real time, after the preset irradiation parameters are corrected (obvious to display remaining time so the operator known long the irradiation will continue, obvious to display the real time parameters so operator can view them as a method of tracking the progress of the irradiation method). Regarding claim 16, Liu et al. in view of Owens et al. disclose the operation method of the monitoring system of claim 12, wherein the correction part adjusts a neutron dosage rate to be a first neutron dosage rate less than a preset neutron dosage rate, in response to the ratio of the real-time neutron dosage to the preset neutron dosage being greater than or equal to the preset value (obvious to reduce dosage rate when cumulative dose is nearly complete because this will prevent accidental overdosage). Regarding claim 17, Liu et al. in view of Owens et al. disclose the operation method of the monitoring system of claim 16, wherein the correction part adjusts the neutron dosage rate to be the first neutron dosage rate less than the preset neutron dosage rate, in response to the ratio of the real-time neutron dosage to the preset neutron dosage being greater than or equal to 97% (obvious as a matter of routine optimization or experimentation, the disclosure never suggests that this value is critical and any value nearing 100% could be considered a reasonable cut-off, with the value chosen being a trade-off between less danger of overdosage with a lower cut-off and shorter irradiation times with a higher cut-off). Regarding claim 18, Liu et al. in view of Owens et al. disclose the operation method of the monitoring system of claim 17, wherein the first neutron dosage rate is comprised between 1/5 and 1/2 of the preset neutron dosage rate (obvious as a matter of routine optimization or experimentation, the disclosure never suggests that this range is critical and any value significantly less than the preset neutron dosage rate could be considered reasonable as a way to reduce the chance of accidental overdosage, with the value chosen representing a trade-off between less risk of overdosage at lower rates and shorter irradiation times at higher rates.). Regarding claim 19, Liu et al. in view of Owens et al. disclose the operation method of the monitoring system of claim 18, wherein the correction part corrects a remaining irradiation time, in response to adjusting, by the correction part, the neutron dosage rate to be 1/5 of the preset neutron dosage rate, and a corrected remaining irradiation time tr is calculated by using a formula (2-4): PNG media_image1.png 82 207 media_image1.png Greyscale where Dtotai is the preset neutron dosage, Dr is the real-time neutron dosage detected by the detection system, and Id is the preset neutron dosage rate (inherent in adjusting the neutron dosage rate to be 1/5 of the preset neutron dosage rate, the irradiation time will need to be adjusted along with the rate for the preset dose to be reached, because dose = rate x time, the formula above merely re-expresses this as remaining time = remaining dose/new rate, were the new rate is 1/5 the preset rate). Regarding claim 20, Liu et al. in view of Owens et al. disclose the operation method of the monitoring system of claim 12, wherein the monitoring system further comprises a storage part configured to store irradiation parameters (obvious to include a storage part because the control will need repeated access this information and storing it ensures access to the preset values even if the values are removed at the input part), a control part configured to perform a therapy plan according to the irradiation parameters stored in the storage part (fig. 3, element 70), and a reading part configured to read the real-time irradiation parameters detected by the detection system (inherent in the use of the detected values in the determination and correction steps). Regarding claim 21, Liu et al. in view of Owens et al. disclose the claimed invention except for the preset value being 90%. The disclosure does not suggest that the specific value of 90% is critical, and any value nearing 100% could be considered a reasonable cut-off, with the value chosen being a trade-off between less danger of overdosage with a lower cut-off and shorter irradiation times with a higher cut-off. Therefore setting the preset value as 90% is obvious as a matter of routine optimization or experimentation. Response to Arguments Applicant’s arguments, see remarks, filed September 9th, 2026, with respect to the prior rejection of claim 9 under 112(b) have been fully considered and are persuasive. The rejection of claim 9 under 112(b) has been withdrawn. Applicant's remaining arguments have been fully considered but they are not persuasive. Applicant argues that Liu does not disclose, either explicitly or inherently, adjusting the dosage rate, teaching only control of the irradiation dose. Examiner agrees, Liu does not explicitly or inherently disclose adjusting the dosage rate. That is why examiner rejected under 103 and not 102. Applicant argues that a person having ordinary skill in the art would understand that the irradiation dose may be controlled using a plurality of factors, such as dosage rate and irradiation time, and one of ordinary skill in the art may choose to achieve the irradiation dose control by merely reducing the irradiation time without adjusting the dosage rate. The fact that a person having ordinary skill in the art could imagine a scenario where the dose rate is not adjusted does not speak for or against whether that person would consider the claimed scenario of adjusting the dosage rate. Applicant the “dose being nearly complete” is such a broad concept that the dosage reduction would be too late and thus ineffective if overdosage already occurred. An obviousness rationale is a line of reasoning showing that there is some indication that a person having ordinary skill in the art would think to do something. It is by its very nature broad. With respect to the independent claim, there is no specific ratio claimed so the claim is just a broad as, and in fact broader than, “nearly complete”, so there is no reason examiner would need to explore the specific level of completeness in her rationale. Regarding new claim 21, applicant argues that the preset value of 90% solves the technical problem of providing a sufficient and smoother adjustment window for dose correction and represents a optimized value found after comprehensive trade-offs. As per MPEP 2144.05, optimization within prior art conditions is obvious if a variable is known to affect a result. It would be clear to an person having ordinary skill in the art at the time the application was filed that the level of completeness used to trigger the reduction in dosage rate would have an effect on the overall length of irradiation as well as the risk of accident overdosage, so a person having ordinary skill would be highly motivated to optimize this parameter. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ELIZA W OSENBAUGH-STEWART whose telephone number is (571)270-5782. The examiner can normally be reached 10am - 6pm Pacific Time M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Kim can be reached at 571-272-2293. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ELIZA W OSENBAUGH-STEWART/Primary Examiner, Art Unit 2881
Read full office action

Prosecution Timeline

Dec 29, 2022
Application Filed
Jan 06, 2026
Non-Final Rejection mailed — §103
Apr 06, 2026
Response Filed
Jun 08, 2026
Final Rejection mailed — §103
Sep 08, 2026
Request for Continued Examination
Sep 10, 2026
Response after Non-Final Action
Sep 21, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12739961
SOURCE MATERIAL DELIVERY SYSTEM, EUV RADIATION SYSTEM, LITHOGRAPHIC APPARATUS, AND METHODS THEREOF
4y 3m to grant Granted Sep 15, 2026
Patent 12728286
METHODS AND SYSTEMS FOR AUTOMATED VOLUMETRIC MODULATED ARC THERAPY (VMAT) FOR EXTERNAL RADIATION THERAPY
3y 4m to grant Granted Sep 08, 2026
Patent 12725754
CAPTIVE SPRING HOOKS FOR REDUCED ELECTROSTATIC STRESS
2y 4m to grant Granted Sep 01, 2026
Patent 12719006
CHARGED PARTICLE BEAM DEVICE
4y 2m to grant Granted Aug 25, 2026
Patent 12704469
PARTICLE-INDUCED X-RAY EMISSION USING LIGHT AND HEAVY PARTICLE BEAMS
2y 8m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
73%
Grant Probability
90%
With Interview (+16.7%)
2y 6m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 689 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month